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Introduction
In congenital bleeding disorders (CBD), the mainstay for the prevention and treatment of bleeding episodes is replacement therapy (RT), the efficacy of which can be indirectly measured through pharmacokinetic (PK) methods based on the assessment of post-infusion factor levels over time (1) . Specific clotting factor levels are currently considered the best determinants of haemostatic correction (1) (2) (3) , and the key element for efficacy evaluation. Post-infusion clotting factor levels depend on RT dose and frequency as well as the PK profiles, which are factor specific.
Currently, little information is available on the PK of activated factor VII (FVIIa) in FVII deficiency, a CBD with an estimated prevalence of one in 500,000 individuals (4) (5) (6) and characterised by large variation in residual FVII levels and clinical phenotypes. Treatment demands for FVII deficiency may vary considerably, ranging from episodic, infrequent factor administrations to high-dose substitutions for prophylaxis or major surgical interventions. These differences in treatment demands mostly depend on the clinical severity of the defect, which may vary from a mild, impaired primary haemostasis-like clinical picture to very severe, lifethreatening and invalidating forms (7, 8) .
Preliminary PK data on recombinant FVIIa (rFVIIa) in patients with FVII deficiency showed a fast clearance and very short half-life (9) ; more recent data demonstrated an increased volume of distribution (10) . Notwithstanding the unfavourable PK data reported (9, 10) , rFVIIa has been successfully used for prophylaxis in patients with FVII deficiency (11) (12) (13) (14) , both in young children and adults (14) . Considering this apparent discrepancy, understanding the PK profile of rFVIIa in patients with FVII deficiency is of paramount importance.
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To evaluate the decline of rFVIIa in the bloodstream, we studied its PK in patients with severe FVII deficiency and compared the 'specific' FVII coagulant activity (FVII:C) assay with a 'global' test, the Prothrombin Time ratio (PTr). Further, extensive in vivo recovery (IVR) evaluations were performed using data collected from a large number of patients treated with rFVIIa, obtained from the Seven Treatment Evaluation Registry (STER).
Materials and methods

Patients
Two cohorts of patients received rFVIIa (NovoSeven ® , Novo Nordisk A/S, Bagsvaerd, Denmark).
The first consisted of 10 non-bleeding patients (6 females, 4 males; median age 43 years, range 9-57 years) with severe FVII deficiency (FVII:C <2%). A complete PK evaluation was performed in these patients after an rFVIIa infusion (16-24 µg kg -1 ; mean 19.7, median 20 µg kg -1 ). The effect of rFVIIa on FVII:C and PTr assays was evaluated pre-dose and 0.17-24 hours (0.17, 0.5, 1, 2, 4, 6, 8, 10 and 24 hours) post-dose (15) using a Non-Compartmental Analysis (NCA) (16) (17) (18) . Doses of rFVIIa have been converted to IU according to the conversion factor 1 µg = 50 IU, because the FVII:C concentration was expressed as IU/dl. To analyse the decay of the PTr data, inverse values (1/PTr) were used to graphically compare the data obtained using FVII:C and PTr; values were expressed as a percentage of the highest post-infusion value (Fig. 1 ).
The second cohort comprised 56 patients (32 females, 24 males; median 23 years, range 2-81) from the multi-centre, prospective, observational, web-based STER (Clinicaltrials.gov identifier: NCT01269138), who required RT with rFVIIa ( Table 1 ). Patients were selected on the basis of a cut-off of FVII:C levels of 26%, as levels higher than this threshold have an uncertain clinical relevance (19, 20) . IVR was evaluated from plasma samples collected prior to and 15 minutes after RT with rFVIIa for prophylaxis, treatment of spontaneous bleeding episodes or surgical interventions. Patients with a FVII inhibitor were excluded from analyses. Only data obtained 6 using high-sensitivity thromboplastins (international sensitivity index [ISI] 1) were included in the IVR analyses to eliminate the influence of the thromboplastin ISI on the clotting assays.
In vivo recovery
Incremental IVR was calculated as the ratio between the post-infusion gain (15 minutes) of FVII and the amount of factor administered according to the following formula:
IVR is expressed as U dl -1 /U kg -1 , MPIL is maximum post-infusion level (U dl -1 ), BL is baseline level (U dl -1 ) and TDA is total dose administered (U kg -1 ).
Statistical analysis
All NCA parameters were calculated using WinNonlin (Pharsight, Cary, NC, USA). Mean and standard deviation were used as position parameters to describe the variable distribution.
Multivariate analysis was performed by running a generalised linear model with conditional gamma distribution and canonical link (21) . This model was chosen because the continuous response variable (IVR) had non-normal distribution on the positive semi-axis with a significant skewness degree. The final model included sex (dichotomous variable), age (continuous variable) and severity (8) . After running the full model with all interactions, variables found not to have a significant effect were removed from the model following a backwards selection criterion.
The analyses were performed using R language version 2.15.2, an open-source programming language and software environment for statistical computing and graphics (www.r-project.com).
Ethics
Data on IVR evaluations were part of the STER, a study approved by the Internal Review Boards (IRBs) of L'Aquila University and all the centres participating in the study. The PK study in 10 patients with a severe FVII deficiency administered rFVIIa in a non-bleeding state was approved by the IRB of the University Hospital in Bratislava and by the IRB of L'Aquila University (22/11/2011; comitato.etico@asl-laquila.it).
Results
IVR evaluations
The IVR distribution following rFVIIa administration in the STER cohort showed a strong positive asymmetry, with values ranging from 0.03 to 2.1 U dl-1/U kg -1 (mean: 0.59; median: 0.46; SD: 0.5). When subjects were grouped according to clinical severity, for major bleeders, significantly higher (p=0.04) IVR values were observed ( Fig. 1 ). Multivariate analysis of the IVR data, which did not show an effect of age (p=0.17) or sex (p=0.41), indicated a significant influence of clinical severity.
PK evaluation
Data pertaining to PK parameters from the 10 non-bleeding patients with severe FVII deficiency are reported in Table 2 . With reference to the dose-independent parameters, the PK data obtained using the FVII:C assay were significantly different from those obtained using the PTr assay ( Table 2) . A very good correlation of parameters over time was observed for both assays (Table 2) ; however, the decay of the 1/PTr curve was less biphasic than that of FVII:C (Fig. 2 ).
Mean residence time (MRT), half-life and terminal half-life of the 1/PTr values were higher in comparison with the corresponding parameters obtained using FVII:C.
Discussion
Here we report the PK of rFVIIa in a large number of patients with severe FVII deficiency, representative of the whole clinical spectrum of FVII deficiency, with the majority of the cohort 8 (66.1%) accounting for symptomatic individuals and more than 20% with severe phenotypes (Table 1) .
We performed extensive IVR evaluations but despite attempts to reduce the IVR variability by restricting the analysis to assays performed with thromboplastins of similar sensitivity (ISI≅1), excluding inhibitor patients and further restricting the cohort to patients with FVII:C levels ≤26%, substantial variation still remained. This finding could not be explained by sex or age; in the multivariate analysis, the only significant determinant of IVR variability was disease severity, which somehow reflected residual FVII expressed by the mutated gene. It is tempting to speculate that the presence of native FVII molecules may influence IVR. All in all, we believe that the low rFVIIa recovery and its variability may mostly be accounted for by a large extravascular distribution volume of rFVIIa, a supposition supported by the finding that the rFVIIa volume of distribution at equilibrium (Vss) was approximately 40 times that of the normal plasma volume ( Table 2 ).
The full PK analysis preformed provided other relevant information including a low rFVIIa area under the curve (AUC), short half-life and fast clearance. In this respect it is worth noting that the terminal-phase half-life of rFVIIa appeared longer than what the MRT or half-life might have indicated. This finding, together with a prolonged pharmacodynamic effect, may be explained by a reduction in factor flow from the plasma pool to the extravascular space at the end of the decay curve, as indicated by the apparent volume of distribution, based on the terminal phase (V z ), being higher than the V ss .
Mathijssen et al (12) described three cases of very severe FVII deficiency treated with rFVIIa prophylaxis in whom a very fast clearance together with very low AUC and t 1/2 (0.51 hour) were 9 observed. Of note, prophylaxis was judged applicable, safe and clinically efficacious (12) . The observations of this case report were considerably strengthened by our own experience with a large number of patients, which showed that prophylaxis schedules based on an average rFVIIa total dose of 100 µg kg -1 per week split into three administrations were efficacious (14) . Such replacement regimens may be regarded as insufficient based on the PK data reported here and in the literature. A possible explanation for the efficacy of prophylaxis may be related to the binding of FVIIa to the perivascular sites (22) from where it would be slowly released. Another possibility is that excess rFVIIa may bind to the endothelial protein C receptor on undamaged endothelial cells (23, 24) ; a morphological study confirmed the occurrence of rapid binding of FVIIa to the endothelium and transfer into the extravascular space, where it is likely to bind to tissue factor (TF) on the pericytes (25) . Through these mechanisms, rFVIIa could remain protected from degradation and, eventually, trigger further generation of thrombin. These cellbased studies provide strong support for our main findings, namely the very large volume of distribution, low IVR and residual clotting activity when FVII:C is no longer detectable (Fig. 2) . In the recent PK study conducted by Mathijssen et al. (10) a large volume of distribution for rFVIIa was also reported and the authors suggested that this finding could explain the prolonged prophylaxis effect and here we provide some clotting-related evidence to this hypothesis.
Mathijssen and colleagues also found that the FVII antigen circulated for a longer time than FVIIa (12) a finding confirmed by their more recent study on PK in FVII deficiency (10) . As FVII antigen does not account for clotting activity, this introduces the question related to what is the most convenient assay for evaluating the PK features of rFVIIa. This issue was also addressed by Scharling et al. (26) , who compared FVII:C with a FVIIa functional assay, showing that the latter was characterised by less variable PK features and more reliable results, especially when assessing low FVII activity levels (<2-3%). To further contribute to this clinically relevant issue, we compared the kinetics of FVII:C to that of PTr. Data were highly comparable ( Table 2) with data obtained from both assays displaying a very good correlation with time (1/PTr 'r' = -0.98 and FVII:C 'r' = -0.99). Using the PTr, PK parameters were characterised by a very slow clearance (about one-quarter of that obtained using FVII:C), a four-times larger AUC and a much longer t 1/2 (Fig. 2) , differences that were all highly significant (all p<0.001). However, there are methodological aspects important to consider when interpreting these results; while the PTr examines an individual's TF pathway as a whole, including the patient's accelerators and inhibitors, the FVII:C assay largely depends on exogenous factors and co-factors provided by the FVII-deficient plasma, very prevalent (at least 10 times) in the assay. This may account for the very different PK results obtained using the two methods, and suggests a potential role for soluble plasma factors. Hence, the FVII:C-based findings may only partially represent the in vivo pro-coagulant potential and therefore provide a poor prediction of efficacy.
A limitation of this study is that the protocol used was limited to a 24-hour observation period, and therefore we did not record the tail of the PTr curve (Fig. 2) . In fact, more than 20% of the 'clotting potential' examined using the PTr was still present 24 hours after rFVIIa infusion, when FVII:C was no longer detectable. The prolonged clotting correction provided by rFVIIa (as detected by the PTr) is in agreement with the observation by Brummel Ziedins (27) .
In conclusion, our data support previous convincing clinical data (11) (12) (13) (14) published on the efficacy of prophylaxis in FVII deficiency, and provides evidence for a large volume of distribution of rFVIIa and the persistence of a clotting potential when FVII:C is no longer detectable. The rapid and substantial diffusion of rFVIIa towards the extravascular spaces would trigger a yet unexplored mechanism to provide pro-coagulant activity for a longer time than expected.
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